BIOFILCHEM vs CONCORDBIO: Stock Comparison

Biofil Chemicals & Pharmaceuticals Limited vs Concord Biotech Limited

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Concord Biotech Limited is the larger company by market capitalisation. Biofil Chemicals & Pharmaceuticals Limited shows faster revenue growth, while Concord Biotech Limited shows a higher dividend yield, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Biofil Chemicals & Pharmaceuticals Limited and Concord Biotech Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, BIOFILCHEM is more favourable on 4 of 11 scored metrics and CONCORDBIO on 6These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CONCORDBIO is the larger company
₹13,119 Cr vs ₹53 Cr
EPS
CONCORDBIO has higher earnings per share
₹24.72 vs ₹1.71
Dividend Yield
CONCORDBIO has a higher dividend yield
0.6% vs 0%
Revenue Growth (TTM YoY)
BIOFILCHEM has faster revenue growth
-9.3% vs -24.1%
EPS Growth (TTM YoY)
BIOFILCHEM has faster EPS growth
10.8% vs -37%
Qtr Sales Growth
BIOFILCHEM has stronger quarterly sales growth
-9.34% vs -24.2%
Qtr Profit Growth
BIOFILCHEM has stronger quarterly profit growth
5% vs -36.8%
ROCE
CONCORDBIO has a higher ROCE
18.2% vs 15.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOFILCHEMCONCORDBIO
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOFILCHEMCONCORDBIO
Live Price₹32.64₹1,256.1
Day Change-0.55%-0.02%
Volume4,04827,927
52-Week High₹46.34₹1,905
52-Week Low₹25.6₹987
Distance from 52W High-29.56%-34.06%

Valuation

MetricBIOFILCHEMCONCORDBIO
Market Cap₹53 Cr₹13,119 Cr
P/E Ratio50.16x
P/B Ratio6.49x
EPS₹1.71₹24.72
Book Value₹13.21₹192.81
Dividend Yield0%0.6%

Growth

MetricBIOFILCHEMCONCORDBIO
Revenue Growth (TTM YoY)-9.3%-24.1%
EPS Growth (TTM YoY)10.8%-37%
Qtr Sales Growth-9.34%-24.2%
Qtr Profit Growth5%-36.8%

Profitability & Leverage

MetricBIOFILCHEMCONCORDBIO
ROE13.8%13.8%
ROCE15.8%18.2%
Net Margin9.81%24.6%
Operating Margin2.29%34.8%
Debt to Equity0.14x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOFILCHEMCONCORDBIO
Promoter Holding46.79%44.08%
FII Holding0%7.52% 0.28 pp
DII Holding0.08%9.36% 0.14 pp
Public Holding53.13%39.03% 0.13 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Biofil Chemicals & Pharmaceuticals Limited and Concord Biotech Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.